News
-
-
COMMUNIQUÉ DE PRESSE
Marinomed Biotech AG publishes remarkable results showing alleviation of allergic eye inflammation in patients treated with Tacrolimus eye drops in peer-reviewed journal
Marinomed Biotech AG publishes study results on Tacrolimus eye drops, showing significant alleviation of allergic eye inflammation. Potential treatment for inflammatory eye diseases -
-
-
COMMUNIQUÉ DE PRESSE
Marinomed Biotech AG reports positive clinical results for unique Carragelose eye drops
Marinomed Biotech AG reports positive clinical results for Carragelose eye drops, improving dry eye symptoms by 54%. The eye drops are well tolerated and hold valid Medical Device Directive certificate -
-
-
COMMUNIQUÉ DE PRESSE
EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share
Marinomed Biotech AG resolves capital increase by issuing 154,053 bearer shares at EUR 5 per share, excluding statutory subscription rights -
-
